

OCT 7 - 2005

**510(k) SUMMARY****SMITH & NEPHEW ANTHOLOGY HIP STEM**

<b>SUBMITTER'S NAME:</b>	Smith & Nephew, Inc., Orthopaedic Division
<b>SUBMITTER'S ADDRESS:</b>	1450 Brooks Road, Memphis, TN 38116
<b>SUBMITTER'S TELEPHONE NUMBER:</b>	901-399-5778
<b>CONTACT PERSON:</b>	Katie Logerot
<b>DATE SUMMARY PREPARED:</b>	September 28, 2005
<b>TRADE OR PROPRIETARY DEVICE NAME:</b>	ANTHOLOGY Hip Stem
<b>COMMON OR USUAL NAME:</b>	Hip Stem
<b>CLASSIFICATION NAME:</b>	21 CFR 888.3358 Hip joint metal/polymer/metal semi-constrained porous-coated uncemented prosthesis
<b>DEVICE CLASS:</b>	Class II
<b>PRODUCT CODE:</b>	Orthopedics/87/LPH, JDI, MEH, LZO

**DEVICE INFORMATION:****A. INTENDED USE:**

The ANTHOLOGY Hip Stem is indicated for individuals undergoing primary and revision surgery where other treatments or devices have failed in rehabilitating hips damaged as a result of trauma or noninflammatory degenerative joint disease (NIDJD) or any of its composite diagnoses of osteoarthritis, avascular necrosis, traumatic arthritis, slipped capital epiphysis, fused hip, fracture of the pelvis, and diastrophic variant.

Hip components are also indicated for inflammatory degenerative joint disease including rheumatoid arthritis, arthritis secondary to a variety of diseases and anomalies, and congenital dysplasia; old, remote osteomyelitis with an extended drainage-free period, in which case, the patient should be warned of an above normal danger of infection postoperatively; treatments of nonunion, femoral neck fracture and trochanteric fractures of the proximal femur with head involvement that are unmanageable using other techniques; endoprosthesis, femoral osteotomy, or Girdlestone resection; fracture-dislocation of the hip; and correction of deformity.

The ANTHOLOGY Hip Stem is for single use only.

**B. DEVICE DESCRIPTION:**

The ANTHOLOGY Hip Stem is manufactured from titanium alloy. The design of the stem is based upon the SYNERGY Hip Stem.

**C. SUBSTANTIAL EQUIVALENCE INFORMATION:**

The substantial equivalence of the ANTHOLOGY Hip Stem is supported by its similarities in design features, overall indications, and material composition to the SYNERGY Hip Stem manufactured and distributed by Smith & Nephew, Inc.

**D. SUMMARY OF TECHNOLOGICAL COMPARISON:**

The intended use, design, and materials of the ANTHOLOGY Hip Stem are substantially equivalent to the SYNERGY Hip Stem. Design Control Activities have been completed and the results indicate that the subject device is safe and effective.



OCT 7 - 2005

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Katie Logerot  
Regulatory Affairs Specialist II  
Smith & Nephew, Inc.  
Orthopaedic Division  
1450 Brooks Road  
Memphis Tennessee 38116

Re: K052792

Trade/Device Name: ANTHOLOGY Hip Stem  
Regulation Number: 21 CFR 888.3358  
Regulation Name: Hip joint metal/polymer/metal semi-constrained  
porous-coated uncemented prosthesis  
Regulatory Class: II  
Product Code: LPH, JDI, MEH, LZO  
Dated: September 29, 2005  
Received: October 3, 2005

Dear Ms. Logerot:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Mark N. Melkerson  
Acting Director  
Division of General, Restorative  
and Neurological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known): K052792

Device Name: Anthology Hip System

### Indications For Use:

The ANTHOLOGY Hip Stem is indicated for individuals undergoing primary and revision surgery where other treatments or devices have failed in rehabilitating hips damaged as a result of trauma or noninflammatory degenerative joint disease (NIDJD) or any of its composite diagnoses of osteoarthritis, avascular necrosis, traumatic arthritis, slipped capital epiphysis, fused hip, fracture of the pelvis, and diastrophic variant.

Hip components are also indicated for inflammatory degenerative joint disease including rheumatoid arthritis, arthritis secondary to a variety of diseases and anomalies, and congenital dysplasia; old, remote osteomyelitis with an extended drainage-free period, in which case, the patient should be warned of an above normal danger of infection postoperatively; treatments of nonunion, femoral neck fracture and trochanteric fractures of the proximal femur with head involvement that are unmanageable using other techniques; endoprosthesis, femoral osteotomy, or Girdlestone resection; fracture-dislocation of the hip; and correction of deformity.

The ANTHOLOGY Hip Stem is for single use only.

Prescription Use   x    
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use   No    
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

  
(Division Sign-Off)

**Division of General, Restorative,  
and Neurological Devices**

Page 1 of   1  

510(k) Number   K052792